Titlebook: Bortezomib in the Treatment of Multiple Myeloma; Irene M. Ghobrial,Paul G. Richardson,Kenneth C. An Book 2011 Springer Basel AG 2011 Borte

無關(guān)緊要

退潮

即席演說

https://doi.org/10.1007/978-3-658-33480-2nosporamide A (NPI-0052). These agents differ from bortezomib in some of their key characteristics, and differences in their pharmacology may result in different activity and safety profiles. This chapter reviews the second-generation proteasome inhibitors, together with other potential therapeutic targets in the ubiquitin–proteasome system.

制度

arrogant

尋找

Second-Generation Proteasome Inhibitors,nosporamide A (NPI-0052). These agents differ from bortezomib in some of their key characteristics, and differences in their pharmacology may result in different activity and safety profiles. This chapter reviews the second-generation proteasome inhibitors, together with other potential therapeutic targets in the ubiquitin–proteasome system.

氣候

2296-6056 s and clinicians from the fields of oncology and pharmacologMultiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsibl

兩種語言

Book 2011 in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

Reverie

Julia Braun,Magdalena Mi?ler-Behrs. The enthusiastic preclinical and clinical results exerted by bortezomib in multiple myeloma, as well as other hematological malignancies including WM, has validated the idea that the proteasome is an important target in cancer therapy.

傲慢物